partnering on small activating RNA (saRNA) therapies to treat neurological diseases. saRNA is an entirely new class of drugs. They are small oligonucleotides, similar to siRNAs. This technology is MiNA’s focus, based on inventions from the company’s founder Pål Saetrom, which were assigned to MiNA by the Norwegian University of Science and Technology. The company has also in-licensed fundamental patents from UT Southwestern Medical Center that covers RNA activation therapeutics.
MiNA will leverage its saRNA platform to identify possible treatments to restore normal cell function in neurological diseases. Servier will handle preclinical and clinical development of potential candidates. Servier also will have the option for commercialization of any products coming out of the partnership.